February 4, 2019
Merck’s PD-1 inhibitor Keytruda (pembrolizumab) outstripped Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (nivolumab) in October-December 2018 global sales including Asia, coming out on top for the first time on a quarterly basis, a Jiho tally shows. Jiho calculated global sales of Opdivo...read more